Literature DB >> 22069043

Adrenocortical carcinoma: effect of hospital volume on patient outcome.

Celestino Pio Lombardi1, Marco Raffaelli, Marco Boniardi, Giorgio De Toma, Luigi Antonio Marzano, Paolo Miccoli, Francesco Minni, Mario Morino, Maria Rosa Pelizzo, Andrea Pietrabissa, Andrea Renda, Andrea Valeri, Carmela De Crea, Rocco Bellantone.   

Abstract

PURPOSE: Optimal management of adrenocortical carcinoma (ACC) involves a detailed diagnostic workup, radical surgery, and appropriate adjuvant therapy. However, due to the rarity of this disease, adequate expertise is necessary to ensure optimal patient care. We evaluated if the experience of a treating center influences the outcome of ACC.
METHODS: Two hundred sixty-three patients who underwent adrenalectomy for ACC were included in a multi-institutional surgical survey and divided into 2 groups: "high-volume center" (HVC) (≥10 adrenalectomies for ACC) and "low-volume center" (LVC) (<10 adrenalectomies for ACC). A comparative analysis was performed.
RESULTS: One hundred seventy-two patients underwent adrenalectomy at HVC and 91 at LVC. The two groups were homogeneous for age, sex, clinical presentation, and stage. The mean lesions size of ACC was higher in HVC than in LVC (104.1 ± 54.6 vs 82.8 ± 41.3 mm; P < 0.001). A significantly higher rate of lymph node dissection (P < 0.01) and of multiorgan resection (P < 0.01) was accomplished in HVC. The number of patients who underwent adjuvant therapy was significantly higher in HVC (P < 0.001). Local recurrence rate was lower in patients treated at HVC (6% vs 18.5%; P = NS). Mean time to recurrence was significantly longer in HVC than in LVC (25.2 ± 28.1 vs 10.1 ± 7.5; P < 0.01).
CONCLUSION: The expertise of dedicated centers had a positive impact on the outcome of patients with ACC, resulting in a lower recurrence rate and improved mean time to recurrence. The improved patient outcome could be related not only to the appropriateness of the surgical procedure, but also to a more adequate multidisciplinary approach.

Entities:  

Mesh:

Year:  2011        PMID: 22069043     DOI: 10.1007/s00423-011-0866-8

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  25 in total

1.  Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma.

Authors:  R D Schulick; M F Brennan
Journal:  Ann Surg Oncol       Date:  1999-12       Impact factor: 5.344

Review 2.  Management of patients with adrenal cancer: recommendations of an international consensus conference.

Authors:  D E Schteingart; G M Doherty; P G Gauger; T J Giordano; G D Hammer; M Korobkin; F P Worden
Journal:  Endocr Relat Cancer       Date:  2005-09       Impact factor: 5.678

3.  Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients.

Authors:  David Brix; Bruno Allolio; Wiebke Fenske; Ayman Agha; Henning Dralle; Christian Jurowich; Peter Langer; Thomas Mussack; Christoph Nies; Hubertus Riedmiller; Martin Spahn; Dirk Weismann; Stefanie Hahner; Martin Fassnacht
Journal:  Eur Urol       Date:  2010-06-22       Impact factor: 20.096

4.  Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.

Authors:  P Icard; P Goudet; C Charpenay; B Andreassian; B Carnaille; Y Chapuis; P Cougard; J F Henry; C Proye
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 5.  Adrenal cortical carcinoma.

Authors:  A P Dackiw; J E Lee; R F Gagel; D B Evans
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

6.  Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.

Authors:  Gwenaelle Abiven; Joel Coste; Lionel Groussin; Philippe Anract; Frédérique Tissier; Paul Legmann; Bertrand Dousset; Xavier Bertagna; Jérôme Bertherat
Journal:  J Clin Endocrinol Metab       Date:  2006-05-02       Impact factor: 5.958

Review 7.  NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma").

Authors: 
Journal:  NIH Consens State Sci Statements       Date:  2002 Feb 4-6

Review 8.  Adrenocortical cancer: pathophysiology and clinical management.

Authors:  Rossella Libè; Amato Fratticci; Jérôme Bertherat
Journal:  Endocr Relat Cancer       Date:  2007-03       Impact factor: 5.678

9.  An eleven-year experience with adrenocortical carcinoma.

Authors:  R F Pommier; M F Brennan
Journal:  Surgery       Date:  1992-12       Impact factor: 3.982

10.  Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty?

Authors:  Henry S Park; Sanziana A Roman; Julie Ann Sosa
Journal:  Arch Surg       Date:  2009-11
View more
  27 in total

1.  Laparoscopic adrenalectomy--10-year experience at a teaching hospital.

Authors:  Sandra Sommerey; Yalda Foroghi; Costanza Chiapponi; Sebastian F Baumbach; Klaus K J Hallfeldt; Roland Ladurner; Julia K S Gallwas
Journal:  Langenbecks Arch Surg       Date:  2015-02-27       Impact factor: 3.445

Review 2.  [Surgical strategies for non-metastatic adrenocortical carcinoma].

Authors:  N Rayes; M Quinkler; T Denecke
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

3.  Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States.

Authors:  Lauren Gratian; John Pura; Michaela Dinan; Shelby Reed; Randall Scheri; Sanziana Roman; Julie Ann Sosa
Journal:  Ann Surg Oncol       Date:  2014-07-29       Impact factor: 5.344

Review 4.  Management of adrenal cancer: a 2013 update.

Authors:  M Terzolo; F Daffara; A Ardito; B Zaggia; V Basile; L Ferrari; A Berruti
Journal:  J Endocrinol Invest       Date:  2014-03       Impact factor: 4.256

Review 5.  Laparoscopic adrenalectomy.

Authors:  Marco Raffaelli; Carmela De Crea; Rocco Bellantone
Journal:  Gland Surg       Date:  2019-07

Review 6.  Surgical management of adrenocortical tumours.

Authors:  Barbra S Miller; Gerard M Doherty
Journal:  Nat Rev Endocrinol       Date:  2014-03-18       Impact factor: 43.330

Review 7.  Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma.

Authors:  Michael R Clay; Emilia M Pinto; Lauren Fishbein; Tobias Else; Katja Kiseljak-Vassiliades
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

8.  Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence.

Authors:  Neda Amini; Georgios Antonios Margonis; Yuhree Kim; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2015-08-18       Impact factor: 5.344

9.  Implications of Conversion during Attempted Minimally Invasive Adrenalectomy for Adrenocortical Carcinoma.

Authors:  Olivia M Delozier; Zachary E Stiles; Benjamin W Deschner; Justin A Drake; Jeremiah L Deneve; Evan S Glazer; Miriam W Tsao; Danny Yakoub; Paxton V Dickson
Journal:  Ann Surg Oncol       Date:  2020-07-11       Impact factor: 5.344

10.  Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database.

Authors:  Paula Marincola Smith; Colleen M Kiernan; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason Prescott; Timothy Pawlik; Tracy S Wang; Jason Glenn; Ioannis Hatzaras; Rivka Shenoy; John Phay; Lawrence A Shirley; Ryan C Fields; Linda Jin; Sharon Weber; Ahmed Salem; Jason Sicklick; Shady Gad; Adam Yopp; John Mansour; Quan-Yang Duh; Natalie Seiser; Konstantinos Votanopoulos; Edward A Levine; George Poultsides; Carmen C Solórzano
Journal:  Ann Surg Oncol       Date:  2018-06-04       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.